Amyotrophic Lateral Sclerosis Market Investigated in In-demand GlobalData Report Published at MarketPublishers.com
09 Jun 2014 • by Natalie Aster
LONDON – Amyotrophic lateral sclerosis (ALS), commonly known as ‘Lou Gehrig’s Disease’, is a rare, but pernicious, progressive neurodegenerative disease, which negatively influence the nerve cells in the spinal cord and in the brain. ALS has a severe impact on physical functioning and primarily presents with muscle twitching, with slurring of speech and/or weakness in a leg or arm. Eventually, people suffering from ALS lose ability to control their muscles needed to speak, move, breathe, eat, which ultimately leads to death. Besides, the progressively degenerative course of the condition is a significant burden for both caregivers and patients, and also for society.
The diagnosed prevalent ALS cases across the 7 major markets (namely the US, the UK, Japan, Italy, France, Spain and Germany) are poised to grow by around 13.5% during the next 10 years. They will increase from 32,698 cases in 2013 to 37,122 cases in 2023. During 2013-2023, the US is expected to register the highest numbers of diagnosed prevalent ALS cases, followed by Japan.
In-demand research report “EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023” worked out by GlobalData presents a comprehensive guide to the world ALS market.
The report presents a detailed overview of the historical and present trends in the worldwide ALS market with a close look at the 7 major markets including the US, the UK, Japan, Italy, France, Spain and Germany. It touches upon the risk factors and comorbidities of the disease; grants access to trustworthy data illustrating the historical and present performance of the ALS market. The research study features the main factors restraining and driving the ALS market growth, reviews the group of patient population, sheds light on the existing treatment options and discusses the key product and pricing issues, outlines the emerging market opportunities. Moreover, a 10-year epidemiological forecast of the diagnosed prevalent ALS cases is available in the report.
EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023
Published: May, 2014
Price: US$ 3,995.00
Other Epidemiology Forecast Reports by GlobalData:
- EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023
- EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023
- EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023
- EpiCast Report: Dengue - Epidemiology Forecast to 2023
- EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2023
More in-demand reports by the publisher can be found at GlobalData page.